CD34-selected stem cell boost as therapy for late graft rejection following allogeneic transplantation for sickle cell disease

Bone Marrow Transplant. 2022 Oct;57(10):1592-1594. doi: 10.1038/s41409-022-01749-9. Epub 2022 Jul 7.

Authors

Hemalatha G Rangarajan¹, Sara A Crowell², Alison S Towerman³, Shalini S Shenoy³

Affiliations

¹ Department of Pediatric Hematology, Oncology, Blood and Marrow Transplant, Nationwide Children's Hospital, Columbus, OH, USA. Hemalatha.rangarajan@nationwidechildrens.org.
² Department of Pediatric Hematology, Oncology, Blood and Marrow Transplant, Nationwide Children's Hospital, Columbus, OH, USA.
³ Department of Pediatrics, Washington University School of Medicine, Saint Louis, MO, USA.

PMID: 35798858
DOI: 10.1038/s41409-022-01749-9

No abstract available

Publication types

Letter

MeSH terms

Anemia, Sickle Cell* / therapy
Antigens, CD34
Graft Rejection / therapy
Graft vs Host Disease*
Hematopoietic Stem Cell Transplantation*
Humans
Stem Cells
Transplantation, Homologous

Substances

Antigens, CD34